TriNetX, a Cambridge, MA-based global health research network that optimizes clinical research and enables discoveries through the creation of real-world evidence (RWE) has raised $40 million in Series D funding. The Series D funding round was led by Merck Global Health Innovation Fund (Merck GHIF) along with new investors Mitsui & Co., Ltd., ITOCHU Technology Ventures, ITOCHU Corporation, and existing investors MPM Capital, F2 Ventures, and Deerfield Management. To date, TriNetX has raised $102M in funding to date.
TriNetX: Democratizing Clinical Research
Founded in 2013, TriNetX’s cloud-based platform, TNX™, provides on-demand access to longitudinal clinical data and a set of highly intuitive analytics capabilities, enabling researchers to explore and compare cohorts, including reviewing cohort characteristics prior to an event and comparing outcomes of interest after the event. The global clinical and claims data representing over 300 million patients available through TriNetX is mapped to controlled terminology and consists of clinical facts from hundreds of healthcare organizations, deep specialty data across all therapeutic areas, and linked medical claims, pharmacy claims and EMR data. TriNetX plans to use the funding to further development of TriNetX’s analytics platform, especially in the areas of artificial intelligence, machine learning and digital clinical trials.
Traction/Recent Milestones
Since TriNetX began commercialization, its customer base has expanded to include 29 industry customers, consisting of nine of the top 15 pharmaceutical companies including Novartis, Sanofi and Pfizer, and five of the top contract research organizations (CROs). TriNetX is powered by an impressive network of healthcare organizations across 17 countries, including the US, UK, Germany, Italy, Japan, Singapore, India and Brazil.
“The landscape for clinical research is changing and TriNetX is leading the disruption as the industry transitions to leveraging data-driven insights to power clinical research and market surveillance,” said Gadi Lachman, CEO of TriNetX. “We’ve created the only real-world evidence ecosystem that brings data, analytics and a researcher community together, to aid in the design of randomized or pragmatic clinical trials and support of observational studies, whether retro- or prospective, controlled or longitudinal.”
